SK Biopharmaceuticals signed an exclusive worldwide license with the Wisconsin Alumni Research Foundation to advance WT-7695, a preclinical radiopharmaceutical developed with the University of Wisconsin–Madison. Under the agreement SK Biopharma gains rights for R&D, manufacturing and commercialization of the candidate. The deal signals growing industry interest in expanding radiopharmaceutical portfolios and outsourcing translational development to companies with commercialization experience. SK Biopharma will lead preclinical optimization and regulatory strategy to position WT-7695 for clinical translation.